spacer
home > ebr > winter 2019 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

Biotechnology companies at the sharp end of the drug discovery process are in a rather unique commercial position of an initial, protracted pre-revenue phase, where best practice in forecasting future value is essential for setting out strategy and for securing investment and commercial partners, as Mirador Analytics’ Jamie Blackport and Chris Watson remind us (page 14). Fast-forward to having, not one, but multiple products launched in various regions, each with distinct and increasingly complex regulatory information requirements, Romuald Braun at AMPLEXOR extols the virtues of pan-project global digitisation for a next-generation approach to regulatory information management (page 86).

The importance of geography, and not underestimating country-specific regulation territories where one might assume all constituent countries were on a level regulatory playing field, is reiterated in Tórben Thers Nřrgaard at PharmaLex Nordics (page 50). Tórben takes a fascinating look at the Scandinavian contrasts between systems and cultures across Norway, Sweden, and Denmark. Expand into the wider Nordic region to include Finland and Iceland, and the complexities and contrasts broaden further. Scandinavia is a recognised hotbed of highly innovative biotech companies. Stephen McNeeney PhD at Potter Clarkson discusses the criticality of these companies ensuring appropriate protection of what is likely to be their only or main significant asset: intellectual property (page 37).

The importance of vaccines as essential weapons in the war against antimicrobial resistance and in preventing difficult-totreat bacterial infections is a topic covered by the team at PnuVax (page 10). Thomas Lingelbach at Valneva explores this deeper in an article focussing on the utility of vaccination against Lyme disease and other preventable illnesses (page 62). Otherwise, advances in spray drying and electron-beam sterilisation techniques could provide solutions to current stability-associated formulation challenges in critical vaccine development, according to Dr Jens Altrichter, Dr Kristina Kemter, Rebekka Ströver, and Professor Dr Martin Scholz at LEUKOCARE (page 28).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Kallik’s Release 6 sets new benchmarks for speed, accuracy and efficiency

Tamworth, UK – 15 June 2019 – Global provider of labelling and artwork management solutions, Kallik, is launching an update to its AMS360 solution – its Release 6, transforming the experience of the business user, whilst defining new benchmarks for speed, accuracy, and efficiency of global labelling and artwork processes.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement